Relationship Between Cancer Type and Impact of PET and PET/CT on Intended Management: Findings of the National Oncologic PET Registry
Authors:
- Bruce E. HillnerBHBruce E. Hillner
- Barry A. SiegelBSBarry A. Siegel
- Anthony F. ShieldsASAnthony F. Shields
- Dawei LiuDLDawei Liu
- Ilana F. GareenIGIlana F. Gareen
- Ed HuntEHEd Hunt
- R. Edward ColemanRCR. Edward Coleman
- 7 November 2008
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 49 (12) , 1928-1935
Abstract
We previously reported aggregate data showing that PET was associated with a change in intended management for over one third of patients participating in the National Oncologic PET Registry (NOPR). Here, we present results for specific cancer types and indications for testing. Methods: The NOPR collected questionnaire data from referring physicians on intended management before and after PET. Data were available from 40,863 PET studies done at 1,368 centers. The impact of PET was assessed for 18 cancer types in patients with pathologically confirmed cancer by type and indication for testing (initial staging, restaging, or detection of suspected recurrence), other than treatment monitoring. Results: When intended management was classified as treatment or nontreatment, physicians changed their intended management for 38.0% of cases (95% confidence interval = 37.6%−38.5%). The frequencies of changes in management ranged from 48.7% for myeloma to 31.4% for nonmelanoma skin cancer. Comparisons across testing indications revealed that only in multiple myeloma did PET have a consistently greater impact on intended management. When the intended management plan before PET was treatment, a change in the intent of treatment (curative vs. palliative) or a major change in the modality of treatment occurred at similar frequencies across different cancer types. Conclusion: The impact of PET on physicians' intended management for patients with known cancer was consistent across cancer types.Keywords
This publication has 8 references indexed in Scilit:
- Impact of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography (PET) Alone on Expected Management of Patients With Cancer: Initial Results From the National Oncologic PET RegistryJournal of Clinical Oncology, 2008
- The National Oncologic PET Registry (NOPR): Design and Analysis PlanJournal of Nuclear Medicine, 2007
- The National Oncologic PET Registry: Expanded Medicare Coverage for PET Under Coverage with Evidence DevelopmentAmerican Journal of Roentgenology, 2007
- Coverage Options For Promising Technologies: Medicare’s ‘Coverage With Evidence Development’Health Affairs, 2006
- Integrated PET/CT: Current Applications and Future DirectionsRadiology, 2006
- Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug DevelopmentClinical Cancer Research, 2005
- Accuracy of Whole-Body Dual-Modality Fluorine-18–2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) for Tumor Staging in Solid Tumors: Comparison With CT and PETJournal of Clinical Oncology, 2004
- Positron emission tomography for prostate, bladder, and renal cancerSeminars in Nuclear Medicine, 2004